Types and associated methodologies of overviews of reviews in health care: a methodological study with published examples

KI Bougioukas, K Pamporis, E Vounzoulaki… - Journal of Clinical …, 2023 - Elsevier
Objectives To provide a descriptive insight into the different types of research
questions/objectives and associated methodologies of overviews of reviews, supplemented …

Genetic and molecular aspects of drug-induced QT interval prolongation

D Baracaldo-Santamaría, K Llinás-Caballero… - International Journal of …, 2021 - mdpi.com
Long QT syndromes can be either acquired or congenital. Drugs are one of the many
etiologies that may induce acquired long QT syndrome. In fact, many drugs frequently used …

The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy

V Zanuso, L Rimassa, C Braconi - Hepatology, 2023 - journals.lww.com
Over the past years, there has been a remarkable advance in the systemic treatment options
for advanced HCC. The overall survival has gradually increased over time, with larger …

Increasing incidence and declining mortality after cancer-associated venous thromboembolism: a nationwide cohort study

AG Ording, F Skjøth, M Søgaard, AA Højen… - The American Journal of …, 2021 - Elsevier
Purpose The incidence of cancer-associated venous thromboembolism has increased, but
whether short-term mortality after cancer-associated venous thromboembolism has changed …

Single‐dose (4.5 mg/m2) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory …

C Dhunputh, M Strullu, A Petit… - British Journal of …, 2022 - Wiley Online Library
Despite major therapeutic improvements, children with relapsed/refractory Acute Myeloid
Leukaemia still have poor outcomes and overall survival does not exceed 40%. New …

[HTML][HTML] Challenges in the use of targeted therapies in non-small cell lung cancer

J Rivera-Concepcion, D Uprety… - Cancer Res Treat, 2022 - synapse.koreamed.org
Precision oncology has fundamentally changed how we diagnose and treat cancer. In
recent years, there has been a significant change in the management of patients with …

Cancer immunotherapies: what the perioperative physician needs to know

RS Ackerman, AR Muncey, NN Aldawoodi… - Current Oncology …, 2022 - Springer
Abstract Purpose of Review For patients with cancer, treatment may include combination
therapy, including surgery and immunotherapy. Here, we review perioperative …

Bevacizumab‐induced mitochondrial dysfunction, endoplasmic reticulum stress, and ERK inactivation contribute to cardiotoxicity

Y Li, W Tian, D Yue, C Chen, C Li… - … Medicine and Cellular …, 2021 - Wiley Online Library
The molecular mechanisms underlying the cardiotoxicity associated with bevacizumab, a
first‐line immunotherapeutic agent used to treat lung cancer, are not fully understood. Here …

Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response

P He, H Wan, J Wan, H Jiang, Y Yang, K Xie… - Frontiers in …, 2022 - frontiersin.org
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third most
common cause of cancer-related death worldwide. Due to asymptomatic patients in the early …

Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: a population-based cohort study

B Daniels, M Aslam, MT van Leeuwen… - The Lancet Regional …, 2023 - thelancet.com
Background Cardiovascular disease (CVD) and cancer are leading causes of death and
people with cancer are at higher risk of developing CVD than the general population. Many …